Development of PRS-400, an inhaled Jagged-1-specific Anticalin® protein for the treatment of muco-obstructive lung diseases. ERS 2022.
PRS-220, a novel inhalable therapeutic intervention for IPF, targeting CTGF directly in the lung. ATS 2022.
The Anticalin-antibody bispecific PRS-352/S095025 strongly stimulates human CD4+ T cells in a PD-L1–dependent manner. AACR 2022.
Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF. ERS 2022.
Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2+ Malignancies. AACR 2021.
Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS- 344/S095012, a 4-1BB/PD-L1 bispecific compound for tumor-localized activation of the immune system. AACR 2021.
A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies.ESMO 2020.
Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2+ Malignancies. SITC 2019.
Bruns IB, Fitzgerald MF, Pardali K, Gardiner P, Keeling DJ, Axelsson LT, Jiang F, Lickliter J, Close DR5 Phase 1 evaluation of the inhaled IL-4Rα antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Rα Abstract: OA5336
Bruns IB, Fitzgerald MF, Mensing G, Tsung M, Pardali K, Gardiner P, Keeling DJ, Axelsson LT, Olsson M, Ghobadi C, Walsh O, McLendon K, Farinola N, Hatchuel L, Close DR. Multiple ascending dose study of the inhaled IL-4Rα antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma.
